BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 29, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for April 13, 2021

April 13, 2021
Biopharmas raising money in public or private financings, including: Arcellx, Briacell, Cerevel, Crinetics, GH, Jaguar, Onxeo, Recursion, Repertoire, Xoma.
Read More
Financial chart

Strong Q1 for med-tech IPOs and VC rounds; total financings raise $13B

April 12, 2021
By Karen Carey
In just one quarter, 14 med-tech companies overall, nearly half the number in 2020, debuted on public markets around the world, and venture capital (VC) financings for the industry have hit a five-year record. The IPOs raised a total of $3.7 billion, a more than 15-fold increase from last year’s first quarter, whereas 107 VC rounds brought in 77% more, or $4.1 billion, in the first quarter (Q1) of 2021.
Read More

Financings for April 12, 2021

April 12, 2021
Med-tech firms raising money in public or private financings, including: Memic Innovative Surgery, Moray Medical, Movia Robotics.
Read More

Financings for April 12, 2021

April 12, 2021
Biopharmas raising money in public or private financings, including: Advaxis, Akoya, Antios, Biomea, Calixar, Valneva.
Read More

Financings for April 9, 2021

April 9, 2021
Med-tech firms raising money in public or private financings, including: Outset Medical.
Read More
Business, data, dollars illustration

Hutchmed closes $100M private placement, expects third China approval and first FDA NDA this year

April 9, 2021
By Elise Mak
The newly renamed Hutchmed (China) Ltd., previously known as Hutchison China Meditech Ltd. (Chi-Med), plans to sell $100 million of its American depository shares at $30.50 per ADS in a private placement to funds affiliated with Baring Private Equity Asia.
Read More

Financings for April 9, 2021

April 9, 2021
Biopharmas raising money in public or private financings, including: Amyris, Artiva, Bionomics, Captor, Cellectis, EV, Intelgenx, Merck & Co., Organon, Reno, Vascular Biogenics, Vectivbio, Werewolf.
Read More

Financings for April 8, 2021

April 8, 2021
Med-tech firms raising money in public or private financings, including: Astrotech, Foxo Technologies, Phreesia, Renalogic.
Read More

Onquality raises combined $35M for cancer supportive care pipeline

April 8, 2021
By David Ho
HONG KONG – Onquality Pharmaceuticals LLC raised an additional $20 million from a series A+ financing round, bringing its amount of capital raised to $35 million.
Read More

Financings for April 8, 2021

April 8, 2021
Biopharmas raising money in public or private financings, including: Amyris, Crinetics, Hutchmed, Ionis, Mind Cure, Otonomy.
Read More
Previous 1 2 … 500 501 502 503 504 505 506 507 508 … 674 675 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing